drugset
drugset / Trial / NCT04426357

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

NCT04426357 ↗

Phase 1 Terminated 6 enrolled Janssen Pharmaceutica N.V., Belgium
Non-randomizedParallel-groupOpen-labelOther

Summary

The main purpose of this study is to evaluate the pharmacokinetics of JNJ-64417184, JNJ-68294291, and JNJ-65201526 after a single oral dose of JNJ-64417184 in adult participants with various degrees of impaired renal function (moderate \[optional\], severe renal impairment, and end stage renal disease (ESRD) not requiring hemodialysis) compared to participants with normal renal function.

Timeline

Start
2020-07-03
Primary completion
2020-11-12
Completion
2020-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64417184 Unknown — Oral

Indications

impaired renal function disease